Nathan Rice

Stock Analyst at Piper Sandler

(3.09)
# 1,192
Out of 5,148 analysts
61
Total ratings
52.63%
Success rate
11.35%
Average return

Stocks Rated by Nathan Rice

Bank First
Jan 26, 2026
Maintains: Neutral
Price Target: $142$150
Current: $138.07
Upside: +8.64%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $41.50
Upside: +15.66%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $43.36
Upside: -3.14%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $31.80
Upside: +10.06%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $81.66
Upside: -9.38%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $156.04
Upside: -46.17%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $189.02
Upside: +4.22%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $26.09
Upside: -65.50%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $636.70
Upside: -31.68%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $290.85
Upside: -19.89%
Initiates: Neutral
Price Target: $83
Current: $44.60
Upside: +86.10%
Initiates: Overweight
Price Target: $15
Current: $19.90
Upside: -24.62%